OncoBriefs - Oncology Research News

March 24, 2026

Immunotherapy Combinations: Oncologists Are Mixing Drugs Like Bartenders and the Results Are Getting Interesting

Immunotherapy Combinations: Oncologists Are Mixing Drugs Like Bartenders and the Results Are Getting Interesting

Single-agent immunotherapy was a good start. Anti-PD-1 alone delivers durable responses in melanoma, lung cancer, and a handful of other tumor types. But for most cancers, monotherapy response rates hover in the 15-25% range, which means the majority of patients get the side effects without the...

March 24, 2026

Poop Pills and Immunotherapy: A Love Story for Stubborn Stomach Cancer

Poop Pills and Immunotherapy: A Love Story for Stubborn Stomach Cancer

Somewhere in Beijing, a team of researchers looked at patients with gastric cancer that had basically told immunotherapy to get lost, and thought: "What if we gave them capsules full of someone else's gut bacteria first?" And honestly? It kind of worked.

March 24, 2026

The Molecular Crumbs Cancer Leaves Behind: ctDNA and the Hunt for Minimal Residual Disease

The Molecular Crumbs Cancer Leaves Behind: ctDNA and the Hunt for Minimal Residual Disease

You have surgery. The tumor comes out. The margins are clear. The scans look clean. Your oncologist says the reassuring words: "We got it all." But did they? In a meaningful number of cases, microscopic cancer cells remain - too few to see on any scan, lurking in tissue or circulation, waiting to...

March 24, 2026

Your Stomach's Rebellion: Why Gastric Cancer Is Finally Meeting Its Match

Your Stomach's Rebellion: Why Gastric Cancer Is Finally Meeting Its Match

Gastric cancer has been playing by its own twisted rules for way too long. While we've been busy celebrating victories against other cancers, stomach tumors have been quietly building an empire in our bellies, becoming the fourth leading cause of cancer death worldwide. But here's the plot twist:...

March 23, 2026

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Stomach cancer has a protein on its surface that was basically hiding in plain sight for decades - and now three drugs are ganging up on it at once, with results that just dropped in Nature Medicine.

March 23, 2026

Fungal Genes Turn T Cells Into Sugar Smugglers That Tumors Can't Rob

Fungal Genes Turn T Cells Into Sugar Smugglers That Tumors Can't Rob

Somewhere in the evolutionary history of wood-rotting fungi, a pair of genes emerged that let mold eat trees. Millions of years later, a team at UCLA looked at those genes and thought: "What if we put these in immune cells to fight cancer?"

March 23, 2026

In Vivo Site-Specific Engineering to Reprogram T Cells

In Vivo Site-Specific Engineering to Reprogram T Cells

Right now, getting CAR-T cell therapy is a bit like ordering a bespoke suit that costs more than your house, takes weeks to tailor, and might not fit by the time it arrives. Doctors pull your T cells out, FedEx them to a specialized lab, genetically rewire them to hunt cancer, grow a few hundred...

March 23, 2026

Robots Read Your Mammogram Now (And They're Weirdly Good at It)

Robots Read Your Mammogram Now (And They're Weirdly Good at It)

Somewhere in a hospital in Córdoba, Spain, a computer just looked at 31,301 mammograms and told radiologists they could skip reading almost two-thirds of them. And the wild part? The computer actually caught more cancers than the humans-only approach.

March 23, 2026

Same Bug, Different Story: How Bacteria Play Both Hero and Villain Inside Tumors

Same Bug, Different Story: How Bacteria Play Both Hero and Villain Inside Tumors

Bacteria have been crashing the cancer party for longer than anyone realized - and it turns out, where they park themselves determines whether they're helping your immune system or actively sabotaging it.

March 23, 2026

Smaller Cuts, Bigger Wins: Keyhole Surgery Beats the Big Slice for Lung Cancer Survival

Smaller Cuts, Bigger Wins: Keyhole Surgery Beats the Big Slice for Lung Cancer Survival

Surgeons have spent centuries perfecting the art of cutting people open. So it's a little ironic that the biggest advancement in lung cancer surgery turns out to be... cutting people open less.